A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors

LESSONS LEARNED: Pancreatic neuroendocrine tumors versus carcinoid tumors should be examined separately in clinical trials. Progression-free survival is more clinically relevant as the primary endpoint (rather than response rate) in phase II trials for low-grade neuroendocrine tumors. BACKGROUND. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Ning, Lubner, Sam J., Mulkerin, Daniel L., Rajguru, Saurabh, Carmichael, Lakeesha, Chenv, Herb, Holen, Kyle D., LoConte, Noelle K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943400/
https://www.ncbi.nlm.nih.gov/pubmed/27261467
http://dx.doi.org/10.1634/theoncologist.2016-0060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943400/
https://www.ncbi.nlm.nih.gov/pubmed/27261467
http://dx.doi.org/10.1634/theoncologist.2016-0060

Ejemplares similares